<DOC>
	<DOC>NCT00077675</DOC>
	<brief_summary>Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.</brief_summary>
	<brief_title>Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Penicillins</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<criteria>Patients must have a diagnosis of one of the following complicated skin and soft tissue infections and either a suspected or confirmed Gram positive organism major abscess requiring surgical incision and drainage infected burn (see exclusion criteria for important qualifications) deep/extensive cellulitis infected ulcer (see exclusion criteria for important qualifications) wound infection Patients must be expected to require at least 4 days of intravenous (IV) antibiotic treatment Previous systemic antibacterial therapy (with the exception of aztreonam and metronidazole) for &gt; 24 hours within 7 days prior to the first dose of study drug unless the pathogen was resistant to prior treatment or the patient was a treatment failure (no clinical improvement after 3 days) Burns involving &gt; 20% of body surface area or third degree/full thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or mediastinitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Abscess</keyword>
	<keyword>Burns</keyword>
	<keyword>Cellulitis</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Wound infections</keyword>
</DOC>